Clinical significance of serum ProGRP detection in patients with small cell lung cancer
10.3969/j.issn.1673-4130.2016.13.007
- VernacularTitle:小细胞肺癌患者血清胃泌素释放肽前体检测的临床意义
- Author:
Zikun LIANG
;
Yan CHEN
;
Changli RONG
;
Yanjun YIN
;
Guangli SHI
- Publication Type:Journal Article
- Keywords:
small cell lung cancer;
gastrin-releasing peptide;
differential diagnosis;
efficacy assessment
- From:
International Journal of Laboratory Medicine
2016;37(13):1765-1766,1769
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical significance of precursor of gastrin‐releasing peptide(ProGRP) for the differen‐tial diagnosis between small cell lung cancer (SCLC) and non‐small cell lung cancer(NSCLC) and efficacy assessment .Methods The levels of ProGRP were detected by ELISA in 210 healthy adults ,200 patients with lung benign disease ,260 patients with NSCLC and 182 patients with SCLC before treatment and after chemotherapy .Results The level of ProGRP in the SCLC group was significantly higher than that in the NSCLC group ,healthy control group and lung benign disease group(P<0 .01) .The sensi‐tivity of ProGRP for detecting SCLC was 56 .3% and the specificity was 92 .6% .When combination detection of ProGRP and NSE was used ,the sensitivity increased to 82 .6% ;the level of ProGRP in the patients with SCLC after 2‐cycle chemotherapy was signifi‐cantly lower than before treatment (P<0 .01) .Conclusion The tumor marker ProGRP has very important guidance significance to assisted diagnosis ,differential diagnosis and efficacy assessment of chemotherapy in the patients with SCLC .
